

Citation: Hu G-y, Tao F, Ji K-w, Wang W (2016) Comparison of Delta-Shape Anastomosis and Extracorporeal Billroth I Anastomosis after Laparoscopic Distal Gastrectomy for Gastric Cancer: A Systematic Review with Meta-Analysis of Short-Term Outcomes. PLoS ONE 11(9): e0162720. doi:10.1371/journal.pone.0162720

Editor: Pei-Yi Chu, Fu Jen Catholic University, TAIWAN

Received: May 5, 2016

Accepted: August 26, 2016

Published: September 15, 2016

Copyright: © 2016 Hu et al. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing Interests: The authors have declared that no competing interests exist.

RESEARCH ARTICLE

Comparison of Delta-Shape Anastomosis and Extracorporeal Billroth I Anastomosis after Laparoscopic Distal Gastrectomy for Gastric Cancer: A Systematic Review with Meta-Analysis of Short-Term Outcomes

Geng-yuan Hu, Feng Tao, Ke-wei Ji*, Wei Wang

Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China

* jikewei_sxph@163.com

Abstract

Objective

The aim of this systematic review and meta-analysis is to evaluate the safety and relative benefits of delta-shape anastomosis (DA) by comparing to conventional laparoscopy-assisted distal gastrectomy with Billroth I gastroduodenostomy (LADG BI).

Methods

Studies and relevant literature regarding DA versus LADG BI were searched in the electronic databases. Operation time, postoperative complications, estimated blood loss, number of retrieved lymph nodes, time to first flatus, time to oral intake, length of postoperative hospitalization in DA and LADG BI were pooled and compared using meta-analysis. Weighted mean differences (WMDs) and odds ratios (ORs) were calculated with 95% confidence intervals (CIs) to evaluate the effect of DA.

Results

Eight studies of 1739 patients were included in the meta-analysis. Compared with LADG BI, DA had shorter postoperative hospitalization (WMD = -0.47, 95%CI: -0.69 to -0.25, P<0.01), less blood loss (WMD = -25.90, 95%CI: -43.11 to -8.70, P<0.01), shorter time to oral intake (WMD = -0.25, 95%CI: -0.49 to -0.01, P = 0.04), and more retrieved lymph nodes (WMD = 1.36, 95%CI: 0.30 to 2.43, P = 0.01). Operation time (WMD = -0.07, 95%CI -15.58 to 15.43, P = 0.99), overall postoperative complication rate (OR = 1.05, 95%CI: 0.74 to 1.49, P = 0.63), surgical complication rate (OR = 1.02, 95%CI: 0.70 to 1.49, P = 0.90), nonsurgical complication rate (OR = 1.21, 95%CI: 0.54 to 2.72, P = 0.64), leakage rate (OR = 2.54, 95% CI: 0.92 to 7.01, P = 0.07), stricture rate (OR = 0.36, 95%CI: 0.09 to 1.44, P = 0.15), wound complication rate (OR = 0.71, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.071, 95%CI: 0.33 to 1.55, P = 0.39), time to first flatus (WMD = 0.05), time to first flatus (WMD = 0.05), time to first flatus (WMD = 0

-0.10, 95%CI: -0.27 to 0.07, P = 0.26), and proximal surgical margin (WMD = -0.25, 95%CI: -1.14 to 0.65, P = 0.59) was not statistically different.

Conclusion

Compared with LADG BI, DA is a safe and feasible procedure, with significantly reduced blood loss, time to oral intake, and postoperative hospitalization.

Introduction

Radical gastrectomy remains the main managements of gastric cancer. Three methods of gastrointestinal tract reconstruction, including the Billroth I (BI) gastroduodenostomy, Billroth II (BII) gastrojejunostomy and Roux-en-Y (R-Y) gastrojejunostomy, are commonly used after distal gastrectomy. Among these methods, the BI anastomosis is especially preferred due to technical simpleness and physiological advantages of allowing food to pass through the duodenum. Besides, postoperative endoscopic examination for biliary tract disorders after BI anastomosis is thought to be easier when compared with that after Billroth II or R-Y anastomosis.

Laparoscopic gastrectomy (LG) has gradually matured and been accepted as a notable alternative to open surgery in the management of gastric cancer [1-3]. More than 90% of patients with early gastric cancer can survive following laparoscopic radical gastrectomy [4-6]. For this population, more comfortable perioperative experience and better postoperative quality of life (QoL) are important goals as well. Usually, surgeons completed the lymph node dissection with laparoscopic techniques and performed gastrointestinal tract reconstruction through the mini-laparotomy, namely laparoscopy-assisted gastrectomy. Advancements in less invasive techniques are ongoing, and many surgeons are attempting to perform totally laparoscopic gastrectomy, which is expected to achieve less invasiveness and better postoperative QoL [7–9]. However, challenges lie in the intracorporeal hand-sewn technique. In 2002, Kanaya et al. described a novel technique named the delta-shaped anastomosis (DA) [10], which was derived from the application of the functional end-to-end technique[11]. The DA completes BI anastomosis just with laparoscopic linear staplers and greatly facilitates intracorporeal BI anastomosis, which gradually gained popularity in Japan, Korea and China [12–14]. Given the critical roles of anastomosis procedure on surgical outcomes, which were still unsettled in DA, we conducted this meta-analysis to clarify the safety and relative benefits of DA by comparing to LADG with Billroth I gastroduodenostomy (LADG BI).

Methods

Literature search

A systematic search was made using PubMed, ISI web of knowledge, Scopus and Embase, from January 2002 to March 2016, to retrieve all published articles comparing DA and LADG BI. The search term was ("delta-shaped anastomosis" or "intracorporeal Billroth I anastomosis") and ("laparoscopic gastrectomy" or "minimally invasive gastrectomy") and ("gastric cancer" or "gastric adenocarcinoma" or "gastric neoplasms"). The "related articles", "similar articles" was also reviewed to broaden the search. The language of publications was restricted in English and Chinese.

Eligibility criteria

All the publications retrieved were included if they were 1) comparing DA with LADG BI; 2) reporting at least 20 patients in each study group; 3) investigating all the primary outcomes in

our standardized questionnaires; and 4) in the event that duplication of data was observed, more recent studies or those with larger sample sizes were preferentially considered. A manual search of the references of all retrieved articles was also carried out to identify publications for possible inclusion.

Exclusion criteria

The following studies or data were excluded: 1) Abstracts, letters, editorials, expert opinions, reviews without original data and case reports; 2) the outcomes and parameters of patients were not clearly reported; 3) it was impossible to extract the appropriate data of the primary outcomes from the published results; and 4) there was an overlap between authors or centers in the published literature.

Data extraction and synthesis

Two reviewers independently undertook literature searches, screened abstracts, and assessed articles met eligibility criteria. The quality of the included studies was assessed using the New-castle-Ottawa Scale (NOS) (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Studies achieving six or more scores were considered to be of high quality and were included in the meta-analysis. Reviewers extracted the following parameters from each study: (1) author and study period; (2) study population characteristics, study design; (3) number of patients operated on with each technique; and (4) preoperative data, intraoperative data and postoperative data. Discrepancies between the two reviewers were resolved by discussion with all co-authors and consensus was reached.

Outcomes of interest

The following outcomes were used to compare the two operative techniques: (1) primary outcomes, which referred to operation time, postoperative stay, overall postoperative complication rate, surgical complication rate, nonsurgical complication rate, anastomotic leakage rate, anastomotic stricture rate, wound complications rate; (2) secondary outcomes, which included estimated blood loss (EBL), time to first flatus, time to oral intake earlier, number of retrieved lymph nodes and proximal surgical margins. The surgical and nonsurgical complication was defined as Jung et al. [15].

Statistical analysis

The meta-analysis was performed using the Review Manager software, version 5.3, provided by the Cochrane Collaboration (http://tech.cochrane.org/revman/download). We analyzed dichotomous variables using the estimation of odds ratios (ORs) with 95% confidence interval (95% CI) and continuous variables using weighted mean differences (WMDs) with a 95% CI. According to the Higgins I² statistic, heterogeneities <25%, 25% to 50%, and >50% were defined as low, moderate, and high, respectively [16]. A fixed-effects model was used for studies with low or moderate statistical heterogeneity [17]. Otherwise, a random-effects model was used for studies more than 50 cases in both DA and LADG BI was conducted. An estimate of potential publication bias was carried out using the funnel plot. P <0.05 was considered statistically significant.

Result

Selected studies characteristics

After selection, eight studies were eventually included in our research [13,19-25] (Fig 1). In total, 755 patients treated with DA and 984 patients treated with LADG BI were included in the




Fig 1. Flow chart of the studies included in the meta-analysis.

doi:10.1371/journal.pone.0162720.g001

analyses (Table 1). All the patients were from Eastern Asia, including Korea, Japan and China. The majority of patients underwent DA were with early gastric cancer (520 out of 755). All of the eight studies were retrospective, nonrandomized. All eight studies were considered to be of adequate quality for the meta-analysis according to NOS assessment (score >5 points) (Table 2).

Primary outcomes

As showed in Fig 2, there was no significant difference between DA and LADG BI regarding the operation time (WMD = -0.07, 95%CI -15.58 to 15.43, P = 0.99). Patients underwent DA

Study	Study period	Country	Study design	Group	Case number	Mean age	Gender (M/F)	BMI	EGC/AGC	Matching criteria
Kinoshita et al.	2007~2009	Japan	R	DA	42	64.7	25/17	23.1	38/4	abcdgh
				LADG BI	41	68.4	30/11	22.8	37/4	
Kim MG et al.	2009~2010	Korea	R	DA	239	56.6	155/84	24	204/35	abfe
				LADG BI	328	55.4	198/130	23.1	312/16	
Kim DG et al.	2009~2012	Korea	R	DA	60	58.3	37/23	23.4	49/11	abceg
				LADG BI	106	55.8	69/37	23.1	90/16	
Wang et al.	2013~2014	China	R	DA	50	64	34/16	23	9/41	abceh
				LADG BI	43	61.2	28/15	22.3	5/38	
Lee et al.	2004~2011	Korea	R	DA	138	62.4	87/51	24.2	94/6	dfgh
				LADG BI	100	56	47/53	22.6	127/11	
Jeong et al.	2013~2014	Korea	R	DA	42	58.4	22/20	24.8	42/0	bcdfgh
				LADG BI	179	62.7	114/65	24.1	167/12	
Lin et al.	2011~2014	China	R	DA	143	60.1	100/43	22.3	48/95	abcg
				LADG BI	143	59.4	102/41	23.5	53/90	
Park et al.	2013~2014	Korea	R	DA	41	61.7	23/18	24.3	36/5	abcdfgh
				LADG BI	44	62.2	24/20	23.4	42/2	

Table 1. Main characteristics of all studies included in the meta-analysis.

M, male; F, female; EGC, early gastric cancer; AGC, advanced gastric cancer; R retrospective; a, age; b, gender; c, BMI; d, comorbidity; e, ASA; f, tumor size; g, tumor stage; h, extend of lymph node dissection.

doi:10.1371/journal.pone.0162720.t001

had a shorter postoperative stay than those underwent LADG BI (WMD = -0.47, 95%CI: -0.69 to -0.25, P<0.01) (Fig 3). Sixty-seven out of 755 patients in the DA group and 86 out of 984 patients in LADG BI group had postoperative morbidities (Table 3). There was no significant difference between two groups (OR = 1.05, 95%CI: 0.74 to 1.49, P = 0.63) (Fig 4A). The pooled effect showed no significant difference between DA and LADG BI in surgical complication

Study		Selection	n		Comparability	C		Total	
	Representativeness of exposed cohort	Selection of nonexposed cohort	Ascertainment of exposure	Outcome not present at the start of the study		Assessment of outcomes	Length of follow- up	Adequacy of follow- up	
Kinoshita et al.	*	*	*	*	**	*	*	*	*****
Kim MG et al.	*	*	*	*	*	*			****
Kim DG et al.	*	*	*	*	**	*	*	*	*****
Wang et al.	*	*	*	*	**	*			****
Lee et al.	*	*	*	*	*	*	*	*	******
Jeong et al.	*	*	*	*	**	*			****
Lin et al.	*	*	*	*	*	*			*****
Park et al.	*	*	*	*	**	*	*	*	******

Table 2. Newcastle-Ottawa Scale assessment of pooled studies.

*, one score.

doi:10.1371/journal.pone.0162720.t002

		DA		LA	NDG BI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
Kinoshita 2011	215	36.1	42	226	38.9	41	11.8%	-11.00 [-27.15, 5.15]	2011	
Kim MG 2011	132.1	26.8	239	104.2	22.7	328	13.4%	27.90 [23.71, 32.09]	2011	+
Kim DG 2013	157.1	43.9	60	197.4	44.5	106	12.2%	-40.30 [-54.27, -26.33]	2013	
Wang 2014	223.4	18.1	50	231.7	22.4	43	13.0%	-8.30 [-16.67, 0.07]	2014	
Lee 2015	220.4	70.5	138	220.5	64.7	100	11.6%	-0.10 [-17.40, 17.20]	2015	
Jeong 2015	142	19	42	116	23	179	13.2%	26.00 [19.34, 32.66]	2015	*
Lin 2016	154.9	30.3	143	153.9	46	143	13.0%	1.00 [-8.03, 10.03]	2016	+
Park 2016	235.3	45	41	235.9	33.3	44	11.7%	-0.60 [-17.53, 16.33]	2016	-
Total (95% Cl)			755			984	100.0%	-0.07 [-15.58, 15.43]		•
Heterogeneity: Tau ² =	461.32	Chi ² =	162.2	1, df = 7	(P < 0	.00001); l ² = 969	%		
Test for overall effect:	Z = 0.01	(P = ().99)							-100 -50 0 50 100 Favours DA Favours LADG BI
Fig 2. Forest plots	of ope	ratio	n time	, DA v	s. LA	DG BI				

doi:10.1371/journal.pone.0162720.g002

rate (OR = 1.02, 95%CI: 0.70 to 1.49, P = 0.90) (Fig 4B) and nonsurgical complication rate (OR = 1.21, 95%CI: 0.54 to 2.72, P = 0.64) (Fig 4C). Regarding the anastomotic leakage, no statistically significant difference was observed (DA *vs.* LADG 10/755 *vs.*5/984; OR = 2.54, 95%CI: 0.92 to 7.01, P = 0.07) (Fig 4D). Two out of 755 patients in the DA group and 6 out of 984 patients in the LADG BI group suffered anastomotic stricture with no significant difference between two groups (OR = 0.36, 95%CI: 0.09 to 1.44, P = 0.15) (Fig 4E). DA had similar wound complications rate compared with LADG BI (OR = 0.71, 95%CI: 0.33 to 1.55, P = 0.39) (Fig 4F).

Secondary outcomes

Secondary outcomes were summarized in Table 4 and Fig 5. Six out of the included studies reported EBL in both groups [13,19,21–24]. A significant reduction in blood loss was observed in the DA compared to LADG BI (WMD = -25.90, 95%CI: -43.11 to -8.70, P<0.01).

As for the postoperative recovery, DA groups had similar time to first flatus (WMD = -0.10, 95%CI: -0.27 to 0.07, P = 0.26). Patients in the DA group started oral intake earlier than those in LADG BI group (WMD = -0.25, 95%CI: -0.49 to -0.01, P = 0.04).

DA retrieved more lymph nodes as compared with LADG BI (WMD = 1.36, 95%CI: 0.30 to 2.43, P = 0.01). Proximal surgical margins were equivalent between two groups (WMD = -0.25, 95%CI: -1.14 to 0.65, P = 0.59).

Nutritional status and postgastrectomy symptoms

Four pooled studies reported the postoperative nutritional status and postgastrectomy symptoms [13,19,22,25], as showed in Table 5. Lee et al. reported DA group had more food intake

		DA		LA	IDG BI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% Cl
Kinoshita 2011	10.6	2.6	42	12	3.5	41	2.8%	-1.40 [-2.73, -0.07]	2011	
Kim MG 2011	6.5	1.4	239	6.9	1.8	328	70.5%	-0.40 [-0.66, -0.14]	2011	_
Kim DG 2013	8.4	4.4	60	8	1.9	106	3.6%	0.40 [-0.77, 1.57]	2013	
Wang 2014	5.5	1.5	50	6.3	2.2	43	8.1%	-0.80 [-1.58, -0.02]	2014	
Lee 2015	7.8	2	138	8.5	5.1	100	4.4%	-0.70 [-1.75, 0.35]	2015	
Jeong 2015	6.9	1.3	42	9.3	13.7	179	1.2%	-2.40 [-4.45, -0.35]	2015	
Lin 2016	12.8	7.4	143	11.9	6.5	143	1.9%	0.90 [-0.71, 2.51]	2016	
Park 2016	8.6	1.4	41	9.3	2.3	44	7.6%	-0.70 [-1.50, 0.10]	2016	
Total (95% Cl)			755			984	100.0%	-0.47 [-0.69, -0.25]		•
Heterogeneity: Chi ² =	11.65, 0	lf = 7	(P = 0.1)	11); I ² =	40%					- + + + + +
Test for overall effect:	Z= 4.13	8 (P ≺	0.0001)						-4 -2 U 2 4 Favours DA Favours LADG BI

Fig 3. Forest plots of length of hospitalization, DA vs. LADG BI.

doi:10.1371/journal.pone.0162720.g003

Study	Group	Case number	Complication
Kinoshita et al	DA	42	Intra-abdominal abscess×2, Wound complications×2, Others×2
	LADG BI	41	Anastomotic stenosis×1, Bleeding×1, Intra-abdominal abscess×1, Wound complications×2, Others×1
Kim MG et al	DA	239	Anastomotic leakage×1, Bleeding×2, Intra-abdominal abscess×3 Wound complications×2, Others×1
	LADG BI	328	Anastomotic leakage×2, Anastomotic stenosis×1, Bleeding×3, Intra-abdominal abscess×4, Wound complications×11
Kim DG et al	DA	60	Anastomotic leakage×1, Delayed gastric emptying×2, Intra-abdominal abscess×2, Wound complications×2, Others×1
	LADG BI	106	Anastomotic leakage×1, Intra-abdominal abscess×4, Others×1
Wang et al	DA	50	Delayed gastric emptying×1, Others×2
	LADG BI	43	Bleeding×1, Others×3
Lee et al	DA	138	Anastomotic leakagex2, Anastomotic stenosisx2, Bleedingx1, Wound complicationsx1, Othersx4
	LADG BI	100	Anastomotic stenosis×4, Wound complications×2, Others×1
Jeong et al	DA	42	Bleeding×1, Delayed gastric emptying×1, Wound complications×1
	LADG BI	179	Anastomotic leakagex2,Anastomotic stenosisx1, Bleedingx3, Intra-abdominal abscessx4, Wound complicationsx11
Lin et al	DA	143	Anastomotic leakage×5, Bleeding×1, Delayed gastric emptying×1, Intra-abdominal abscess×3, Others×12
	LADG BI	143	Bleeding×2, Delayed gastric emptying×1, Intra-abdominal abscess×3, Others×8
Park et al	DA	41	Anastomotic leakage×1, Wound complications×1, Others×3
	LADG BI	44	Anastomotic leakage×1, Intra-abdominal abscess×1, Others×2

Table 3. Details of postoperative morbidities in pooled studies.

doi:10.1371/journal.pone.0162720.t003

[22]. Park et al. reported DA group maintained higher albumin postoperatively [25]. Kim et al. and Park et al. found more patients in the DA group suffered reflux [13,25]. No difference was revealed between the DA group and LADG BI group regarding nausea, dyspepsia, diarrhea and dumping syndrome.

Subgroup analysis

Subgroup analysis of the pooled studies was performed to evaluate whether the pooled primary outcomes and secondary outcomes altered in different case volume subgroup. Subgroup analysis regarding the surgical outcomes had similar results as above (Table 6).

Publication bias

A funnel plot was constructed for the overall postoperative complications and showed symmetry, suggesting that publication bias was acceptable and was unlikely to drive conclusions (Fig 6).

Discussion

Totally laparoscopic gastrectomy is increasingly used since its debut in 1992 [26]. Several meta-analyses hinted totally laparoscopic distal gastrectomy (TLDG), pooling miscellaneous intracorporeal anastomosis including DA, BII and R-Y, has equivalent feasibility and safety as LADG [27–29]. More importantly, TLDG is seemingly less invasive and more suitable for the obese than LADG. Potential heterogeneity arises from different intracorporeal anastomosis in

 LADG BI

 Events
 Total
 Events
 Total
 Weight

 6
 42
 6
 41
 8.5%

 9
 239
 21
 328
 27.1
 328
 27.4

 8
 60
 6
 106
 6.1%
 3
 50
 4
 3
 6.1%

 3
 50
 4
 23
 8.7
 10.0
 12.8%

 11
 138
 7
 100
 12.8%
 22.4
 15%
 4.43
 6.5%
 22
 143
 14
 143
 19.4%
 Odds Ratio M-H, Fixed, 95% C1 Year 0.97 [0.29, 3.30] 2011 0.57 [0.26, 1.27] 2011 1.56 [0.84, 7.78] 2013 0.62 [0.13, 2.95] 2014 0.50 [0.14, 1.73] 2015 1.15 [0.43, 3.08] 2015 1.38 [0.35, 5.57] 2016 1.68 [0.82, 3.42] 2016 Odds Ratio M-H, Fixed, 95% Cl Study or Subgroup Kinoshita 2011 Kim MG 2011 Kim DG 2013 Wang 2014 Jeong 2015 Lee 2015 Park 2016 Lin 2016
 Total (95% CI)
 755
 984

 Total events
 67
 86

 Heterogeneity: Chi^P = 8.36, df = 7 (P = 0.30); P = 16%
 Test for overall effect: Z = 0.28 (P = 0.78)
 984 100.0% 1.05 [0.74, 1.49] 0.01 0.1 1 10 Favours DA Favours LADG BI 100
 DA
 LADG BI
 Odds Ratio

 Study or Subaroup
 Events
 Total
 Events
 Total
 Weight
 M.H., Fixed, 95% CI
 Year

 Kinoshka 2011
 6
 42
 6
 41
 9.9%
 9.7[0.25, 3.0]
 2011

 Kinoshka 2011
 9
 23.9
 21.38
 82.2%
 5.7[0.26, 1.27]
 2011

 Kim Do 2013
 7
 60
 5
 106
 6.0%
 2.67[0.8], 1.80!
 2013

 Vang 2014
 2
 50
 3
 4.5
 5.8%
 0.56[0.09, 3.49]
 2014

 Jeong 2015
 3
 42
 20
 179
 13.3%
 0.61 [0.17, 2.16]
 2015

 Lin 2016
 10
 138
 7
 100
 14.2%
 1.04 [0.30, 2.03]
 2015

 Lin 2016
 15
 14.3
 8.143
 1.35%
 1.08 [0.8] (.42.2]
 2015

 Lin 2016
 14.3
 8.44
 5.1%
 1.08 [0.21, 5.67]
 2016
 Odds Ratio M-H, Fixed, 95% Cl -
 Total (95% CI)
 755
 984

 Total events
 55
 73

 Heterogeneity: Chi^P = 7.68, df = 7 (P = 0.36); P = 9%
 755
 756

 Test for overall effect: Z = 0.12 (P = 0.90)
 755
 756
 984 100.0% 1.02 [0.70, 1.49] 0.01 0.1 1 10 Favours DA Favours LADG BI 100

С

A

В

	DA		LADG	BI		Odds Ratio			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year		M-H, Fixed, 95% C	<u> </u>	
Kim MG 2011	0	239	0	328		Not estimable	2011				
Kinoshita 2011	0	42	0	41		Not estimable	2011				
Kim DG 2013	1	60	1	106	6.7%	1.78 [0.11, 28.98]	2013				
Wang 2014	1	50	1	43	9.9%	0.86 [0.05, 14.13]	2014				
Lee 2015	1	138	0	100	5.4%	2.19 [0.09, 54.38]	2015				-
Jeong 2015	0	42	4	179	16.1%	0.46 [0.02, 8.69]	2015	-	•	-	
Lin 2016	7	143	6	143	53.4%	1.18 [0.39, 3.59]	2016				
Park 2016	2	41	1	44	8.6%	2.21 [0.19, 25.28]	2016				
Total (95% CI)		755		984	100.0%	1.21 [0.54, 2.72]			-		
Total events	12		13								
Heterogeneity: Chi ² =	0.92, df=	5 (P =	0.97); 12=	= 0%				0.01 0		10	4.00
Test for overall effect	Z = 0.47	P = 0.6	54)						1 1 avours DA Favours	10 LADG BI	100

D

	DA		LADG	BI		Odds Ratio			Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year		M-H, Fixe	ed, 95% Cl	
Kinoshita 2011	0	42	0	41		Not estimable	2011				
Kim MG 2011	1	239	2	328	34.6%	0.68 [0.06, 7.60]	2011				
Kim DG 2013	1	60	1	106	14.6%	1.78 [0.11, 28.98]	2013			•	
Wang 2014	0	50	0	43		Not estimable	2014				
Jeong 2015	0	42	2	179	19.6%	0.84 [0.04, 17.72]	2015				
Lee 2015	2	138	0	100	11.7%	3.68 [0.17, 77.52]	2015			•	
Lin 2016	5	143	0	143	9.9%	11.40 [0.62, 208.06]	2016		-	•	
Park 2016	1	41	0	44	9.6%	3.30 [0.13, 83.23]	2016			•	-
Total (95% CI)		755		984	100.0%	2.54 [0.92, 7.01]				•	
Total events	10		5								
Heterogeneity: Chi ² =	2.82, df=	= 5 (P =	0.73); l ² =	= 0%				0.005	1	1	
Test for overall effect	Z=1.79	(P = 0.0)7)					0.005	0.1 Favours DA	1 10 Favours LADG BI	200

Е

	DA		LADG	BI		Odds Ratio			Odds F	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M	-H, Fixed	, 95% CI	
Kinoshita 2011	0	42	1	41	20.5%	0.32 [0.01, 8.03]	2011	-	•		
Kim MG 2011	0	239	1	328	17.2%	0.46 [0.02, 11.24]	2011	-	•		
Kim DG 2013	0	60	0	106		Not estimable	2013				
Wang 2014	0	50	0	43		Not estimable	2014				
Lee 2015	2	138	4	100	62.3%	0.35 [0.06, 1.97]	2015				
Jeong 2015	0	42	0	179		Not estimable	2015				
Park 2016	0	41	0	44		Not estimable	2016				
Lin 2016	0	143	0	143		Not estimable	2016				
Total (95% CI)		755		984	100.0%	0.36 [0.09, 1.44]					
Total events	2		6								
Heterogeneity: Chi ² =	0.03, df=	2 (P =	0.99); I2:	= 0%				0.01 0.1	-	10	
Test for overall effect:	Z=1.44	(P = 0.1	5)						urs DA	10 Favours LAD	

F

	DA		LADG	BI		Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year		M-H, Fixed, 95% Cl
Kinoshita 2011	2	42	2	41	12.3%	0.97 [0.13, 7.27]	2011		
Kim MG 2011	2	239	11	328	58.5%	0.24 [0.05, 1.11]	2011		
Kim DG 2013	2	60	0	106	2.2%	9.10 [0.43, 192.79]	2013		
Nang 2014	0	50	0	43		Not estimable	2014		
Lee 2015	1	138	2	100	14.6%	0.36 [0.03, 4.00]	2015	20	
Jeong 2015	1	42	4	179	9.4%	1.07 [0.12, 9.80]	2015		
Park 2016	1	41	0	44	3.0%	3.30 [0.13, 83.23]	2016		
Lin 2016	0	143	0	143		Not estimable	2016		
Fotal (95% CI)		755		984	100.0%	0.71 [0.33, 1.55]			•
Total events	9		19						
Heterogeneity: Chi ^z =	6.00. df=	5 (P =	0.31); F=	= 17%				0.001	0.1 1 10 1000

Fig 4. Forest plots of postoperative complication, DA vs. LADG BI. (A) overall postoperative complication, (B) surgical complication, (C) nonsurgical complication, (D) anastomotic leakage, (E) anastomotic stricture, and (F) wound complication.

doi:10.1371/journal.pone.0162720.g004

these studies and obscures the veritable efficacy of each method. To obtain a more reliable comparison on the feasible and safety of DA, we conducted this systematic review and metaanalysis of published articles that directly compared the DA with LADG BI.

There is no consensus on the indications of DA yet. The decision of DA usually resides with surgeons' or patients' preferences [13,20,23]. DA was mostly applied in early gastric cancer (EGC) located in the low third stomach, which combined indications of LG and conventional BI anastomosis [23,25]. Indications were also expanded to locally advanced gastric cancers (AGC) along with the accumulating surgeons' experiences [20,21,24]. Remarkably, radical treatment of AGC usually requires longer surgical margin than EGC, which increases the anastomosis tension and results in related complications. Lin et al. reported patients with AGC underwent DA had a higher risk of anastomotic leakage [24]. Identifying the lesion precisely during the operation and achievement of enough surgical margin is crucial in deciding the methods of anastomosis. Distinguishing from LADG BI, DA is deficient with tactility in detecting the lesion of EGC merely by the laparoscopic grasper. Preoperative or intraoperative endoscopy is quite practical to mark the lesion as recommended by quite a few of surgeons [19,20].

Prolonged operation time is a common concern of laparoscopic surgery. Our meta-analysis revealed DA wasn't inferior to LADG BI in this outcome. By using the liner stapler, DA has much saved the anastomosis time as well as the total operation time. In experienced hands, the operation time of LG with DA can be shorter than open gastrectomy and laparoscopy-assisted gastrectomy [13,20,23,24,30]. But this doesn't mean the DA is easy. Conversely, coordination between the surgeon and assistants is especially technically demanding. During joining the posterior walls of duodenum and stomach together, appropriate traction by the assistant is of great importance. Given the majority of studies included in our meta-analysis were conducted by surgeons well-trained in LG, or even in DA, outcomes may be discrepant in the non-specially trained surgeons. Kanaya et al. and Jeong et al. revealed the learning curve of DA was quite steep for laparoscopic surgeons [23,30]. After around 10~15 cases, time of completing DA would reach a plateau and maintain in 10~25 min.

Comparing with LADG BI, the potential benefits of DA are better cosmesis, less blood loss and less postoperative pain. Usually, the surgical incision in LADG BI is longer than DA. By hiding the largest surgical incision around the umbilicus, patients undergo DA appears to be scarless. Avoiding the mini-laparotomy for gastrointestinal anastomosis, DA is totally intracorporeal and more tense-free, which reduces the risk of injury around the anastomosis. These characteristics of DA contribute to less intraoperative blood loss, less postoperative pain and more comfortable experience presenting as lower pain score and less administration of

Outcomes	Pooled studies	Sample size	Pooled effect	Pooled estimates	95% CI	P value	l ²
EBL	6	1087	Random	WMD -25.90	-43.11, -8.70	<0.01	83%
Time to first flatus	7	1654	Random	WMD -0.10	-0.27, 0.07	0.26	71%
Time to first oral taking	6	1561	Fixed	WMD -0.25	-0.49, -0.01	0.04	60%
Retrived lymph nodes	7	1573	Fixed	WMD 1.36	0.30, 2.43	0.01	45%
Proximal surgical margin	4	1111	Random	WMD -0.25	-1.14, 0.65	0.59	86%

Table 4. Meta-analyses results for DA vs. LADG BI.

EBL, estimated blood loss; WMD, weighted mean difference; OR, odds ratio.

doi:10.1371/journal.pone.0162720.t004

		DA			ADG BI			Mean Differen			Mean Difference
Study or Subgroup			Total				Weigh				IV, Random, 95% Cl
Kinoshita 2011	21.2		42	62.5	81.6	41	14.09				
Kim DG 2013		44.5	60	68.2	71	106	17.79				
Wang 2014	64.2	22	50	74.3	22.3	43	20.49				
Jeong 2015	50	39	42	105	69	179	18.49				
Lee 2015	99.8	99	138	133.3		100	11.79				
Lin 2016	51.1	31.4	143	63	101.2	143	17.89	% -11.90 [-29.27	, 5.47]	2016	
Total (95% CI)			475			612	100.0	% -25.90 [-43.11,	-8.701		•
Heterogeneity: Tau ² :	= 355 57	Chi ² =		df = 5.6	- < U U(
Test for overall effect											-100 -50 0 50 100
			,								Favours DA Favours LADG BI
3											
		A		LADO				Mean Difference			Mean Difference
Study or Subgroup	Mean	SD T	otal I	Mean S	D Tot	al W	eight r	V, Random, 95% Cl	Year		IV, Random, 95% Cl
Kim MG 2011	3	0.7	239	3.2 0	.7 32	28 21	0.1%	-0.20 [-0.32, -0.08]	2011		+
Kinoshita 2011	2.1	0.8	42	2.4 0	.7 4	11 1:	2.4%	-0.30 [-0.62, 0.02]			
Kim DG 2013		0.9	60	3.1 0			4.5%	0.40 [0.14, 0.66]			
Wang 2014		0.9	50	3.2 1			3.7%	-0.40 [-0.81, 0.01]			
Lee 2015			138	2.8 0			7.8%	-0.10 [-0.28, 0.08]			
		0.7	42	2.8 0			4.3%				
Jeong 2015 Lip 2016			42					0.00 [-0.27, 0.27]			
Lin 2016	3.9	1.0	143	4.1 1	.6 14	+3 1	1.2%	-0.20 [-0.56, 0.16]	2010		
Total (95% CI)			714			10 10		-0.10 [-0.27, 0.07]			•
Heterogeneity: Tau ² =				= 6 (P =	0.002)	² = 7	1%				-1 -0.5 0 0.5 1
Test for overall effect	∠=1.12	(P = 0.	.26)								Favours DA Favours LADG BI
-											
	D	٨		LADO	BI			Mean Difference			Mean Difference
Study or Subgroup			otal N		D Tot	al We		A Random, 95% Cl	Year		IV, Random, 95% Cl
Kinoshita 2011	2.3	1	42	2.7 1	.6 4		.2%	-0.40 [-0.98, 0.18]			
Kim MG 2011	3.6		239	4 1				-0.40 [-0.59, -0.21]			+
Kim DG 2013		3.3	60	5.7 1			5.1%	0.30 [-0.57, 1.17]			_
Jeong 2015	1.3		42	1.8 1				-0.50 [-0.81, -0.19]			
Lee 2015	4.6		42	4.9 0			0.1%				
Lin 2016	5.2	1.9						-0.30 [-0.62, 0.02] 0.30 [-0.12, 0.72]			+
Lin 2016	5.2	1.9	143	4.9 1			5.0%	-0.30 [-0.62, 0.02] 0.30 [-0.12, 0.72]			+ - -
Lin 2016 Total (95% Cl)	5.2				.7 14		6.0%				•
			143 664	4.9 1	.7 14 89	13 18 17 10	5.0% 0 .0 %	0.30 [-0.12, 0.72]		+	
Total (95% CI)	= 0.05; Ch	i² = 12	143 664 48, df	4.9 1	.7 14 89	13 18 17 10	5.0% 0 .0 %	0.30 [-0.12, 0.72]		-4	-2 0 2 4 Favours DA Favours LADG BI
Total (95% Cl) Heterogeneity: Tau² =	= 0.05; Ch	i² = 12	143 664 48, df	4.9 1	.7 14 89	13 18 17 10	5.0% 0 .0 %	0.30 [-0.12, 0.72]		 -4	-2 0 2 4 Favours DA Favours LADG BI
Total (95% Cl) Heterogeneity: Tau² =	= 0.05; Ch	i² = 12	143 664 48, df	4.9 1 = 5 (P =	.7 14 89 0.03); I	13 18 17 10	5.0% 0 .0 %	0.30 [-0.12, 0.72]		-4	
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	= 0.05; Ch : Z = 2.01	i² = 12 (P = 0. DA	143 664 48, df 04)	4.9 1 = 5 (P = LA	.7 14 89 0.03); I DG BI	13 18 0 7 10 1 ² = 609	5.0% 0.0 % %	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference	2016		Favours DA Favours LADG BI
Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect	= 0.05; Ch Z = 2.01 (i² = 12 (P = 0. DA	143 664 48, df 04)	4.9 1 = 5 (P =	.7 14 89 0.03); I DG BI	13 18 0 7 10 1 ² = 609	5.0% 0 .0 %	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference	2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	= 0.05; Ch : Z = 2.01	i² = 12 (P = 0. DA	143 664 48, df 04)	4.9 1 = 5 (P = LA	.7 14 89 0.03); I DG BI <u>SD 1</u>	13 18 0 7 10 1 ² = 609	5.0% 0.0 % %	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference IV, Fixed, 95% CI	2016 Year		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	= 0.05; Ch : Z = 2.01 [Mean	i ² = 12 (P = 0. DA <u>SD</u> 13	143 664 .48, df 04) Total	4.9 1 = 5 (P = LA <u>Mean</u>	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1	13 16 1 7 10 17 = 609 Fotal	3.0% 0.0% % <u>Weight</u>	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42]	2016 Year 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² Test for overall effect D Study or Subgroup Kinoshita 2011 Kim MG 2011	= 0.05; Ch Z = 2.01 <u>Mean</u> 35.9 35.2	i ² = 12 (P = 0. DA <u>SD</u> 13 11.3	143 664 48, df 04) <u>Total</u> 42 239	4.9 1 = 5 (P = LAI <u>Mean</u> 34.1 33.3	.7 14 89 0.03);1 DG BI <u>SD 1</u> 13.1 12.5	13 18 17 10 1 ⁷ = 60 1 ⁹ 10 10 10 10 10 10 10 10 10 10 10 10 10	5.0% 0.0% % <u>Weight</u> 3.6% 29.1%	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference IV, Fixed, 95% CI 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87]	2016 Year 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014	= 0.05; Ch Z = 2.01 <u>Mean</u> 35.9 35.2 32.9	i ² = 12 (P = 0. DA <u>SD</u> 13 11.3 4.5	143 664 48, df 04) <u>Total</u> 42 239 50	4.9 1 = 5 (P = LAI <u>Mean</u> 34.1 33.3 34.1	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4	43 18 07 10 ¹⁷ = 60 ⁴ <u>1</u> <u>1</u> <u>1</u> <u>1</u> <u>1</u> <u>1</u> <u>1</u> <u>1</u>	5.0% 0.0% % <u>Weight</u> 3.6% 29.1% 27.2%	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference IV. Fixed, 95% CI 1.80 [-3.82, 7.42] -1.20 [-3.24, 0.84]	2016 Year 2011 2011 2014		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Lee 2015	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3	i ² = 12 (P = 0. DA <u>SD</u> 13 11.3 4.5 14.8	143 664 48, df 04) <u>Total</u> 42 239 50 138	4.9 1 = 5 (P = LAI <u>Mean</u> 34.1 33.3 34.1 37	.7 14 89 0.03);1 DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4	43 18 07 10 1 = 60 ⁴ 1 = 60 ⁴ 	5.0% 0.0% % <u>Weight</u> 3.6% 29.1% 27.2% 8.7%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.24, 0.84]	2016 Year 2011 2011 2014 2015		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect D Study or Subaroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36	i ^a = 12 (P = 0. DA <u>SD</u> 13 11.3 4.5 14.8 11	143 664 48, df 04) <u>Total</u> 42 239 50 138 42	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34	.7 14 89 0.03);1 DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12	43 18 7 10 7 10	5.0% 0.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.0%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76]	2016 Year 2011 2014 2015 2015		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36 39	i ² = 12 (P = 0. DA SD 13 11.3 4.5 14.8 11 11.3	143 664 48, df 04) <u>Total</u> 42 239 50 138 42 41	4.9 1 = 5 (P = LA <u>Mean</u> 34.1 33.3 34.1 37 34 38	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12 12	43 16 7 10 7 10	5.0% 0.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.0% 4.6%	0.30 [-0.12, 0.72] -0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95]	2016 Year 2011 2011 2014 2015 2015 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect D Study or Subaroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36	i ² = 12 (P = 0. DA SD 13 11.3 4.5 14.8 11 11.3	143 664 48, df 04) <u>Total</u> 42 239 50 138 42	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34	.7 14 89 0.03);1 DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12	43 18 7 10 7 10	5.0% 0.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.0%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76]	2016 Year 2011 2011 2014 2015 2015 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI)	= 0.05; Ch Z = 2.01 o Mean 35.9 35.2 32.9 38.3 36 39 35.7	i [≈] = 12 (P = 0. SD 13 11.3 4.5 14.8 11 11.3 11.3 11.5	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34 38 31.7	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12 12 9.6	13 16 $10 100^7 $	5.0% 0.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.0% 4.6%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference IV. Fixed, 95% CI 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.0, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46]	2016 Year 2011 2014 2015 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² =	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36 39 35.7 : 10.94, df	P = 12 (P = 0. (P = 0. 13 11.3 4.5 14.8 11 11.3 11.5 = 6 (P	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 P = 0.09	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34 38 31.7	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12 12 9.6	13 16 $10 100^7 $	5.0% D.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.7% 4.6% 18.8%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.0, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46]	2016 Year 2011 2014 2015 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI)	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36 39 35.7 : 10.94, df	P = 12 (P = 0. (P = 0. 13 11.3 4.5 14.8 11 11.3 11.5 = 6 (P	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 P = 0.09	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34 38 31.7	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12 12 9.6	13 16 $10 100^7 $	5.0% D.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.7% 4.6% 18.8%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.0, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46]	2016 Year 2011 2014 2015 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² =	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36 39 35.7 : 10.94, df	P = 12 (P = 0. (P = 0. 13 11.3 4.5 14.8 11 11.3 11.5 = 6 (P	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 P = 0.09	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34 38 31.7	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12 12 9.6	13 16 $10 100^7 $	5.0% D.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.7% 4.6% 18.8%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.0, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46]	2016 Year 2011 2014 2015 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² =	= 0.05; Ch Z = 2.01 Mean 35.9 35.2 32.9 38.3 36 39 35.7 : 10.94, df	P = 12 (P = 0. (P = 0. 13 11.3 4.5 14.8 11 11.3 11.5 = 6 (P	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 P = 0.09	4.9 1 = 5 (P = <u>LAI</u> 34.1 33.3 34.1 37 34 38 31.7	.7 14 89 0.03); I DG BI <u>SD 1</u> 13.1 12.5 5.4 13.4 12 12 9.6	13 16 $10 100^7 $	5.0% D.0% % Weight 3.6% 29.1% 27.2% 8.7% 8.7% 4.6% 18.8%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.0, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46]	2016 Year 2011 2014 2015 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect C Stuck or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	= 0.05; Ch Z = 2.01 (Mean 35.9 35.2 32.9 38.3 36 39 35.7 : Z = 2.51	i ² = 12 (P = 0. SD 13 11.3 4.5 11 11.3 11.5 = 6 (P (P = 0. • A	143 664 .48, df 04) <u>Total</u> 42 239 50 138 42 41 143 695 P = 0.09 .01)	4.9 1 LA Mean 34.1 37 34.3 31.7 34.3 31.7 34.1 37 34.1 37 34.1 37 34.1 37 34.1 38 31.7 44 54 54 54 54 54 54 54 54 54	7 14 89 0.03); i 0G BI 13.1 12.5 5.4 12 12 9.6 5%	 13 18 107 100 107 100 108 108 100 179 143 143 878 	8.0% 0.0% % 0.0% % 0.0% 0.0% 0.0% 0.0% 0	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.00 [-3.25, 0.84] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference	2016 Year 2011 2011 2015 2015 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect D Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jacong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect F Study or Subgroup	= 0.05; Ch Z = 2.01 Mean 1 3 5 .9 3 3 3 3 5 .9 3 3 5 .2 3 3 5 .2 3 5 .2 3 5 .2 3 5 .2 3 3 5 .7 3 5 .7 3 5 .7 3 5 .7 3 5 .7 3 5 .7 3 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5 .7 5	i [≥] = 12 (P = 0. DA SD 13 11.3 4.5 11.3 11.3 11.3 (P = 0. (P = 0. A SD T	143 664 .48, df 04)	4.9 1 LAA Mean 34.1 33.3 34.1 37 34 38 31.7 34 38 31.7 34 38 31.7 LADO Mean S	7 14 89 0.03); I DG BI 13.1 12.5 5.4 13.4 12 12 9.6 5% 5% 5 5%	 13 18 107 100 107 100 107 100 107 100 108 43 100 179 44 143 878 878 al West 	8.0% 0.0% % 0.0% % 0.0% 0.0% 0.0% 0.0% 0	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV, Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>J. Random, 95% CI</u>	2016 Year 2011 2014 2015 2015 2016 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect F Study or Subgroup Kinoshita 2011	= 0.05; Ch Z = 2.01 (Mean 35.9 32.9 38.3 36 39 35.7 : Z = 2.51 (Mean 0	P = 12 P = 0. 13 11.3 4.5 14.8 11.3 11.3 11.5 = 6 (P (P = 0. (P = 0.) A SD T 0	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 c'= 0.06 .01) 0 0 0 0	4.9 1 LAN Mean 33.3 34.1 37 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.3 34.1 37 34.1 38 31.7 24.5	7 14 89 0.03); 00 Bl <u>50 1</u> 13.1 12.5 5.4 13.4 12.5 5.4 13.4 12.5 5.4 13.4 12.5 5.4 13.5 5.5 5.4 13.5 5.5 5.4 13.5 5.5 5.4 13.5 5.5 5.4 13.5 5.5 5.4 13.5 5.5 5.5 13.5 5.5 5.5 5.6 13.5 5.5 5.6 13.5 5.5 5.6 13.5 5.5 5.5 5.6 1.5 5.5 5.6 1.5 5.5 5.6 5.6 5.6 5.6 5.6 5.6 5	 13 18 17 100 10 100 10 100 41 328 43 43 100 179 44 143 878 878 al We 0 	8.0% 0.0% % 9.0% 29.1% 29.1% 8.0% 4.6% 18.8% 100.0%	0.30 [-0.12, 0.72] .0.25 [-0.49, -0.01] Mean Difference <u>IV, Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 324, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V, Random, 95% CI</u> Not estimable	2016 Year 2011 2011 2014 2015 2016 2016 2016 Year 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity, Tau ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect F Study or Subgroup Kinoshita 2011 Kim MG 2011	= 0.05; Ch Z = 2.01 o 35.9 35.2 32.9 38.3 36 39 35.7 : 10.94, df : Z = 2.51 D Mean 0 4.1	P = 12 P = 0. DA <u>SD</u> 13 11.3 4.5 14.8 11.3 11.3 11.5 = 6 (P (P = 0. KA SD T 0 2	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 °= 0.09 01) otal M 0 239	4.9 1 LA A Mean 34.1 33.3 34.1 37 34 31.7 31.7 31.7 31.7 31.7 34 31.7 31.7 34	7 14 85 0.03); 1 0 0 0 0 1 1 1 1 1 1 2 5 4 1 2 1 2 9.6 5 8 5 8 5 8 5 8 5 5 8 5 5 8 5 5 8 5 5 8 5 5 8 5 5 8 5 5 8 5 5 5 5 4 1 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	13 18 7 10 0 7 10 0 7 = 60° 41 328 43 100 179 44 143 878 878 al Wa 0 28 25	8.0% 0.0% % 0.0% % 0.0% 0.0% 0.0% 0.0% 0	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] 1.20 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.96] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable -0.20 [-0.53, 0.13]	2016 Year 2011 2011 2014 2015 2016 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect D Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jaeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect F Study or Subgroup Kinoshita 2011 Kim MG 2013	= 0.05; Ch Z = 2.01 35.9 35.2 32.9 38.3 36 39 35.7 :10.94, df :Z = 2.51 0 Mean 0 4.1 0	P= 12 (P = 0. SD 13 11.3 4.5 14.8 11.3 11.5 = 6 (P (P = 0. A SD T 0 2 0	143 664 .48, df 42 239 50 138 42 143 695 01) 01 0 01 0 0 0 0 0 0 0	4.9 1 LAA Mean 34.1 33.3 34.1 37 34 38 31.7 34 38 31.7 34 30 31.7 4 30 31.7 32 34 38 31.7 30 30 31.7 32 32 32 32 32 32 32 32 32 32	.7 14 85 0.03); i 0 0 0 0 12.5 5.4 13.4 12.5 5.4 13.4 12.5 5.4 13.4 12.5 5.4 13.4 12.5 5.4 13.4 5.6 5.6 5.6 5.6 5.6 5.6 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7	13 18 17 100 17 100 18 100 17 41 328 43 100 179 44 143 878 al We 0 0 0	8.0% 0.0% % 9.0% 29.1% 29.1% 8.0% 4.6% 18.8% 100.0%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.32, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable -0.20 [-0.53, 0.13] Not estimable	2016 Year 2011 2014 2015 2016 2016 2016 2016 2016 2016 2016 2016		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect E Study or Subgroup Kinoshita 2011 Kim MG 2011 Kim MG 2013	= 0.05; Ch Z = 2.01 o 35.9 35.2 32.9 38.3 36 39 35.7 : 10.94, df : Z = 2.51 D Mean 0 4.1	P = 12 P = 0. DA <u>SD</u> 13 11.3 4.5 14.8 11.3 11.3 11.5 = 6 (P (P = 0. KA SD T 0 2	143 664 .48, df 04) Total 42 239 50 138 42 41 143 695 °= 0.09 01) otal M 0 239	4.9 1 LA A Mean 34.1 33.3 34.1 37 34 31.7 31.7 31.7 31.7 31.7 34 31.7 31.7 34	.7 14 85 0.03);1 0G BI 12 12 5.4 12 12 9.6 58 58 58 56 10 70 0 2 32 0 0	I3 18 7 100 7 = 60° 100 179 44 143 878 878 878 878 0 28 28 0 28 28 0	6.0% 0.0% % Weight 3.6% 29.1% 27.2% 4.6% 18.8% 100.0% P eight N	0.30 [-0.12, 0.72] .0.25 [-0.49, -0.01] Mean Difference <u>IV, Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 33, 24, 30] 2.00 [-1.76, 5.76] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>I, Random, 95% CI</u> Not estimable 0.20 [-0.53, 0.13] Not estimable	2016 Year 2011 2014 2015 2016 2016 2016 2016 Year 2011 2011 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect D Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jaeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect F Study or Subgroup Kinoshita 2011 Kim MG 2013	= 0.05; Ch Z = 2.01 35.9 35.2 32.9 38.3 36 39 35.7 : Z = 2.51 0 Mean 0 4.1 0 0 0	P= 12 (P = 0. SD 13 11.3 4.5 14.8 11.3 11.5 = 6 (P (P = 0. A SD T 0 2 0	143 664 .48, df 42 239 50 138 42 143 695 01) 01 0 01 0 0 0 0 0 0 0 0 0 0 0 0 0	4.9 1 LAA Mean 34.1 33.3 34.1 37 34 38 31.7 34 38 31.7 34 38 31.7 4 38 31.7 4 38 31.7 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1	.7 14 85 0.03);1 0G Bl 13.1 12.5 5.4 12 12 9.6 5.8 12 12 9.6 5.8 5.8 10 0 10 2 3 2 0 0 0	I3 18 7 100 7 = 60° 100 179 44 143 878 878 878 878 0 28 28 0 28 28 0	6.0% 0.0% % Weight 3.6% 29.1% 27.2% 4.6% 18.8% 100.0% P eight N	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.32, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable -0.20 [-0.53, 0.13] Not estimable	2016 Year 2011 2014 2015 2016 2016 2016 2016 Year 2011 2011 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity, Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect F Study or Subgroup Kinoshita 2011 Kim MG 2011 Kim Scilla 2013 Kim Scilla 2015 Kim	= 0.05; Ch Z = 2.01 o 35.9 35.2 32.9 38.3 36 39 35.7 : Z = 2.51 0 Mean 0 4.1 0 0 4.2	P = 12 P = 0. P =	143 664 .48, df 04) Total 42 239 50 138 42 239 50 138 42 41 143 695 >= 0.05 .01) otal N 0 0 0 0 0 0 0	4.9 1 LAA Mean 34.1 33.3 34.1 33.3 34.1 37 34.1 38 31.7 LADC LADC 0 4.3 0 0	.7 14 85 0.03);1 DG BI <u>50 1</u> 13.1 12.5 5.4 13.4 12. 5.4 12. 9.6 5.8 9.6 5.8 0 0 Tot 0 2 32 0 0 0 0 . 9, 17	I3 18 77 100 77 100 77 100 78 100 100 1179 44 143 1143 878 81 We 28 23 00 28 20 0 20 20	6.0% 0.0% % Weightt 3.6% 29.1% 27.2% 8.0% 4.6% 18.8% 100.0% P eight N	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] 1.20 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.96] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable -0.20 [-0.53, 0.13] Not estimable -1.90 [-2.90, -0.90]	2016 Year 2011 2014 2015 2016 2016 2016 2016 2016 2016 2016 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	= 0.05; Ch Z = 2.01 35.9 35.2 32.9 38.3 36 39 35.7 :10.94, df :Z = 2.51 0 Mean 0 4.1 0 0 4.1 0 0 5	P = 12 P = 0. P =	143 664 .48, df 42 239 50 138 42 41 143 695 = 0.06 .01) 0 0 0 0 0 42 138 42 41 143 0 0 0 0 0 0 0 0 0 0 0 0 0	4.9 1 LAA Mean 34.1 33.3 34.1 33.3 34.1 37 34 38 31.7 34 38 31.7 4.3 0 0 4.3 0 0 6.1 4 4.2 2	.7 14 85 0.03); 1 0.03); 1 10.05 5.0 13.1 12.5 5.4 12. 12. 9.6 5.4 13.4 12. 12. 9.6 5.4 13.4 12. 12. 9.6 5.4 13.4 12. 2. 3%	13 16 77 100 77 100 7 100 328 43 100 179 44 143 878 878 80 22 00 0 20 0 20 20	6.0% 0.0% % Weiaht 3.6% 29.1% 27.2% 8.0% 4.6% 8.7% 8.0% 4.6% 18.8% 100.0% 10.0%	0.30 [-0.12, 0.72] .0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable	2016 Year 2011 2014 2015 2015 2016 2016 2016 2016 2016 2016 2016 2016 2016 2016 2016 2016 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2015 2016 2017 2017 2017 2017 2016 2016 2016 2016 2016 2016 2017		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Constitute of the second Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect Kinoshita 2011 Kim MG 2011 Kim Sci 2011 Kim MG 2011 Kim MG 2013 Wang 2014 Jeong 2015	= 0.05; Ch Z = 2.01 o 35.9 35.2 32.9 38.3 36 39 35.7 : Z = 2.51 0 Mean 0 4.1 0 0 4.2	$i^{2} = 12$ (P = 0.) 13 11.3 11.3 11.4.5 11.5 $i^{2} = 6 (P = 0.)$ $i^{2} = 0.0$ $i^{2} = 0.0$ i	143 664 .48, df 42 239 50 138 42 41 143 695 = 0.05 .01) otal M 0 239 0 42 239 0 42	4.9 1 LA A Mean 34.1 33.3 34.1 37 34 31.7 31.7 31.7 31.7 31.7 34 31.7 31.7 31.7 31.7 31.7 34 31.7	.7 14 885 0.03);1 DG BI <u>5D 1</u> 13.1 12.5 5.4 12 9.6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	13 16 7 100 7 100 7 100 7 100 17 100 179 41 100 179 44 143 878 878 878 0 28 25 0 0 29 25 0 0 0 0 0 0 0 0 0 0 0 0 0	6.0% 0.0% % Weiaht 3.6% 29.1% 27.2% 8.0% 4.6% 8.7% 8.0% 4.6% 18.8% 100.0% 10.0%	0.30 [-0.12, 0.72] 0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] 1.20 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.96] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable -0.20 [-0.53, 0.13] Not estimable -1.90 [-2.90, -0.90]	2016 Year 2011 2014 2015 2016 2016 2016 2016 2016 2016 2016 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jaong 2015 Park 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Kim MG 2011 Kim MG 2013 Wang 2014 Jeong 2015 Lee 2015 Lin 2016 Park 2016	= 0.05; Ch Z = 2.01 (Mean 35.9 35.2 32.9 38.3 36 39 35.7 : 2 = 2.51 (Mean 0 4.1 0 0 4.1 0 0 4.2 5 5 0	$i^{2} = 12$ (P = 0.) 13 13 14.8 11.3 14.8 11.3 11.5 $i^{2} = 6 (P = 0.)$ $i^{2} = 0$ $i^{2} = $	143 664 48, df 42 239 50 138 42 41 143 695 = 0.06 01) 0 0 0 0 0 0 41 138 0 41	4.9 1 LAA Mean 34.1 33.3 34.1 37 34.1 38 31.7 0 0 0 0 0 0 0 0 0 0 0 0 0	.7 14 85 0.03);1 DG BI 13.1 12.5 5.4 12. 12. 9.6 5.4 13.4 12. 9.6 5.4 13.4 12. 9.6 5.4 13.4 12. 2.9 5.6 5.4 13.4 2. 2.32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	13 16 7 100 7 100 7 100 7 100 7 100 1 1 328 43 100 179 44 143 878 878 878 878 0 0 0 0 0 0 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 0 26 26 26 26 26 26 26 26 26 26	6.0% 0.0% % 0.0	0.30 [-0.12, 0.72] .0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable 0.20 [-0.53, 0.13] Not estimable 0.10 [-0.94, 1.14]	2016 Year 2011 2014 2015 2016 2016 2016 2016 2016 2016 2016 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jeong 2015 Park 2016 Lin 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect Study or Subgroup Kinoshita 2011 Kim MG 2011 Kim MG 2011 Kim MG 2013 Wang 2014 Jeong 2015 Lin 2016 Park 2016 Total (95% CI)	= 0.05; Ch Z = 2.01 35.9 35.2 32.9 38.3 36 39 35.7 :10.94, df :Z = 2.51 0 Mean 0 4.1 0 4.1 0 4.2 5 5 0 5	$i^{2} = 12$ (P = 0. SD 13 11.3 4.5 14.8 11 11.3 11.5 $i^{2} = 6$ (P ($P = 0.$ SD 2 0 0 2.3 0 2.3	143 664 .48, df 04) 142 239 50 138 422 239 0 138 422 41 143 695 C= 0.05 01) 0 239 0 0 42 138 0 0 41 143 0 41 0 41 143 0 41 0 138 42 143 0 138 42 143 0 138 42 143 0 138 42 143 0 0 138 42 143 0 0 0 138 41 143 0 0 0 0 0 0 0 0 0 0 0 0 0	4.9 1 LAA Mean 34.1 33.3 34.1 37 34.1 38 31.7 4.1 30 30 3.1 4.1 30 30 31.7 30 4.1 30 30 30 31.7 30 4.1 30 30 30 30 4.1 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 4.1 30 30 4.1 30 4.3 30 4.1 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3	.7 14 88 0.03);1 DG BI <u>SD 1</u> 13.1 12.5 5.4 12 9.6 5.4 12 9.6 5.4 12 9.6 5.5 12 9.6 5.5 12 9.6 5.5 12 0 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 0 17 .2 10 0 0 0 17 .2 10 0 0 0 0 17 .2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	13 16 7 100 7 100 7 100 7 100 7 100 1 1328 41 1 328 43 1 00 1 79 44 1 43 878 878 878 878 0 28 0 28	8.0% 0.0% % Weight 3.6% 29.1% 8.0% 8.0% 8.7% 100.0% 1 0.4% 2.2% 0.7% 0.0%	0.30 [-0.12, 0.72] .0.25 [-0.49, -0.01] Mean Difference <u>IV, Fixed, 95% CI</u> 1.90 [-0.07, 32, 7.42] 1.90 [-0.07, 32, 7.42] 1.90 [-0.07, 32, 7.42] 1.90 [-3.24, 0.84] 1.30 [-2.30, 4.90] 2.00 [-1.76, 5.76] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>IV, Random, 95% CI</u> Not estimable -0.20 [-0.53, 0.13] Not estimable 1.90 [-2.90, -0.90] 0.80 [0.18, 1.42] Not estimable	2016 Year 2011 2014 2015 2016 2016 2016 2016 2016 2016 2016 2011 2011		Favours DA Favours LADG BI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Wang 2014 Lee 2015 Jaong 2015 Park 2016 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Study or Subgroup Kinoshita 2011 Kim MG 2011 Kim MG 2011 Kim MG 2013 Wang 2014 Jeong 2015 Lee 2015 Lin 2016 Park 2016	= 0.05; Ch Z = 2.01 35.9 35.2 32.9 38.3 36 39 35.7 10.94, df : Z = 2.51 0 Mean 0 4.1 0 0 4.1 0 0 4.2 5 5 0 5	i [≠] = 12 (P = 0. 13 13 11.3 4.5 14.8 11.3 11.3 11.5 = 6 (P (P = 0. (P = 0. 0 2 2.3 2.3 2.3 i [≠] = 20	143 664 48, df 42 239 50 50 138 42 42 138 695 5°=0.05 01) 01 143 0239 0 42 138 0 42 138 0 42 138 0 42 138 0 0 138 0 143 0 0 0 0 0 0 0 0 0 0 0 0 0	4.9 1 LAA Mean 34.1 33.3 34.1 37 34.1 38 31.7 4.1 30 30 3.1 4.1 30 30 31.7 30 4.1 30 30 30 31.7 30 4.1 30 30 30 30 4.1 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 30 4.1 30 4.1 30 30 4.1 30 4.3 30 4.1 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 30 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3	.7 14 88 0.03);1 DG BI <u>SD 1</u> 13.1 12.5 5.4 12 9.6 5.4 12 9.6 5.4 12 9.6 5.5 12 9.6 5.5 12 9.6 5.5 12 0 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 17 .2 10 0 0 17 .2 10 0 0 0 17 .2 10 0 0 0 0 17 .2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	13 16 7 100 7 100 7 100 7 100 7 100 1 1328 41 1 328 43 1 00 1 79 44 1 43 878 878 878 878 0 28 0 28	8.0% 0.0% % Weight 3.6% 29.1% 8.0% 8.0% 8.7% 100.0% 1 0.4% 2.2% 0.7% 0.0%	0.30 [-0.12, 0.72] .0.25 [-0.49, -0.01] Mean Difference <u>IV. Fixed, 95% CI</u> 1.80 [-3.82, 7.42] 1.90 [-0.07, 3.87] -1.20 [-3.24, 0.84] 1.30 [-3.30, 4.90] 2.00 [-1.76, 5.76] 1.00 [-3.95, 5.95] 4.00 [1.54, 6.46] 1.36 [0.30, 2.43] Mean Difference <u>V. Random, 95% CI</u> Not estimable 0.20 [-0.53, 0.13] Not estimable 0.10 [-0.94, 1.14]	2016 Year 2011 2014 2015 2016 2016 2016 2016 2016 2016 2016 2011 2011		Favours DA Favours LADG BI

Fig 5. Forest plots of secondary outcomes, DA vs. LADG BI. (A) EBL, (B) time to first flatus, (C) time to first oral taking, (D) number of retrived lymph nodes, and (E) proximal surgical margin.

doi:10.1371/journal.pone.0162720.g005

Study	Length of follow- up		Nutri	tional stat	us	Total lymphocyte count	Assesment terms of gastrointestinal symptoms	Postgastrectomy symptoms					
		Food intake	Body weight	Serum albumin	Total cholesterol			Reflux	Nausea	Dyspepsia	Diarrhea	Dumping syndrome	
Kinoshita et al.	3 months		NS	NS	NS		questionnaire	NS	NS	NS	NS	NS	
Kim DG et al.	3 months		NS				questionnaire	Ļ		NS	NS	NS	
Lee et al.	46 months (mean)	Ţ	NS			NS	questionnaire and endoscopy examination	Ļ		NS		NS	
Park et al.	1 year		NS	Î	NS	NS	questionnaire	NS	NS		NS		

NS, no significance; \downarrow , worse; \uparrow , better.

doi:10.1371/journal.pone.0162720.t005

analgesics. In the studies by Kim et al. and Wang et al., postoperative pain score was significantly lower in DA than in the LADG BI[20,21]. Kinoshita et al. reported the acute inflammatory response following operation was milder in DA with a placid elevation of C-reactive protein [19]. In the present study, data from pooled studies were insufficient to evaluate the postoperative pain and acute inflammatory response. The evaluation of these parameters after DA will be sufficiently assessed by prospective RCTs only.

Acceptable postoperative complication of DA was observed in the present study, which was equivalent to LADG BI and even lower than open distal gastrectomy as historical reports [31,32]. Anastomosis-related complication such as leakage and stricture can be disastrous. There was a higher leakage rate in DA (DA vs. LADG BI, 10/755 vs.5/984), but it did not achieve a significant statistical difference. Kim et al. proposed mobilization of the duodenum until the gastroduodenal artery exposure to make sufficient duodenal stump, which eased the tension of anastomosis and might reduce the risk of anastomotic leakage [20]. DA contained several cutting edges, which may cause poor blood supply, yield more weak points around the anastomosis and result in leakage. Huang et al. modified the DA by resection the intersection of the duodenal cutting edge and the common closed edge at the same time to lessen the anastomotic weak point [33,34]. In contrast to leakage, DA group has less anastomotic stricture (2/ 755 vs.6/984). In LADG BI the size of anastomosis ring depends on the diameter of the circular stapler, while a large anastomosis ring can be easily achieved with the 45-mm linear stapler in DA. However, we should also admit the fact that the sample size was still too small to reveal the real benefits and drawbacks of DA because of the low risk of anastomotic leakage and stricture as reported.

Milder surgical trauma and comparable postoperative morbidity brought substantial clinical superiority. Patients in the DA group were able to resume oral intake earlier and have a shorter length of hospitalization, which could counteract the higher expense of DA technique itself. Enhanced recovery program was also applied in some included studies, which emphasized earlier oral intake and might contribute to these advantages of DA in some degrees. Apart from this, LADG BI had more severe complications demanded reoperation or other interventions, which postponed the discharge.

An unexpected result of our study was that the DA retrieved more lymph nodes than LADG BI. It didn't mean the DA was superior to LADG BI in lymphadenectomy because this


Table 6. Subgroup analyses results for DA vs. LADG BI.

Outcomes	Pooled studies	Sample size	Pooled estimates	95% CI	P value
Operation time	8	1739	WMD -0.07	-15.58, 15.43	0.99
\leq 50 cases	4	482	WMD 2.01	-19.32, 23.34	0.85
>50 cases	4	1257	WMD -2.43	-30.81, 25.96	0.87
Length of hospitalization	8	1739	WMD -0.47	-0.69, -0.25	<0.01
\leq 50 cases	4	482	WMD -0.94	-0.60, -0.10	<0.01
>50 cases	4	1257	WMD -0.35	-1.44, -0.44	<0.01
Overall postoperative complication	8	1739	OR 1.05	0.74, 1.49	0.78
\leq 50 cases	4	482	OR 1.05	0.41, 1.50	0.46
>50 cases	4	1257	OR 1.19	0.78, 1.81	0.41
Surgical complication	8	1739	OR 1.21	0.54, 2.72	0.64
\leq 50 cases	4	482	OR 1.01	0.24, 4.25	0.99
>50 cases	4	1257	OR 1.32	0.49, 3.52	0.58
Nonsurgical complication	8	1739	OR 1.02	0.70, 1.49	0.90
≤50 cases	4	482	OR 0.78	0.38, 1.57	0.48
>50 cases	4	1257	OR 1.15	0.73, 1.81	0.54
Anastomotic leakage	8	1739	OR 2.54	0.92, 7.01	0.07
\leq 50 cases	4	482	OR 1.64	0.22, 12.16	0.63
>50 cases	4	1257	OR 2.90	0.87, 9.66	0.08
Anastomotic stricture	8	1739	OR 0.36	0.09, 1.44	0.15
\leq 50 cases	4	482	OR 0.32	0.01, 8.03	0.49
>50 cases	4	1257	OR 0.38	0.08, 1.71	0.21
Wound complication	8	1739	OR 0.71	0.33, 1.55	0.39
\leq 50 cases	4	482	OR 1.29	0.35, 4.77	0.70
>50 cases	4	1257	OR 0.53	0.20, 1.41	0.20
EBL	6	1087	WMD -25.90	-43.11, -8.70	<0.01
\leq 50 cases	3	397	WMD -34.72	-67.60, -1.85	0.04
>50 cases	3	690	WMD -13.89	-25.51, -2.27	0.02
Time to first flatus	7	1654	WMD -0.10	-0.27, 0.07	0.26
\leq 50 cases	3	397	WMD -0.20	-0.45, 0.04	0.11
>50 cases	4	1257	WMD -0.03	-0.28, 0.21	0.8
Time to first oral taking	6	1561	WMD -0.25	-0.49, -0.01	0.04
≤50 cases	2	304	WMD -0.48	-0.75, -0.21	<0.01
>50 cases	4	1257	WMD -0.12	-0.47, 0.23	0.51
Retrived lymph nodes	7	1573	WMD 1.36	0.30, 2.43	0.01
≤50 cases	4	482	WMD -0.13	-1.74, 1.49	0.88
>50 cases	3	1091	WMD 2.50	1.09, 3.92	<0.01
Proximal surgical margin	4	1111	WMD -0.25	-1.14, 0.65	0.59
≤50 cases	2	306	WMD -0.91	-2.87, 1.05	0.37
	2	805	WMD 0.26	-0.71, 1.24	0.60

EBL, estimated blood loss; WMD, weighted mean difference; OR, odds ratio.

doi:10.1371/journal.pone.0162720.t006

procedure is supposed to be identical for both approaches. We deemed surgeons' experience played an important role as the majority of surgeons converted to DA after they had matured LADG BI [13,19]. Both DA and LADG BI achieved proximal resection margins more than 3cm that was believed to improve oncological outcomes[35]. Pooled analysis also demonstrated these two approaches achieved similar proximal surgical margins and overall survival rate.



doi:10.1371/journal.pone.0162720.g006

Large anastomotic ring and straightforward passageway from the esophagus to the duodenum allow fast gastric emptying and permit more food intakes. More food intake and better nutritional status was observed in DA group during long-term follow-up [22]. Clinically significant postgastrectomy symptoms will deteriorate postoperative QoL. Without the barrier of the pylorus, large anastomosis ring of DA has the concern of reflux gastritis, which makes patients uncomfortable and increases in risk of gastric remnant cancer [36–38]. Against with this hypothesis, several studies reported the rate of reflux gastritis after DA was acceptable and comparable with conventional LADG BI and R-Y. Both Kanaya et al. and Lee et al. reported DA had a prevalence of bile reflux but was not a clinical problem [22,30]. Other symptoms are also concerned. Twisting duodenum after DA appears to cause gastric stasis and gastroesophageal reflux. On the other hand, twisting duodenum happened to ward off dumping syndrome in some degree. According to the follow-up result, DA had a similar risk of these symptoms as LADG BI as showed in Table 4.

This meta-analysis had several limitations which should be taken into consideration in interpreting the conclusions of this study. First, this meta-analysis pooled eight retrospective studies which may bias the interpretation of their results. Though well-designed randomized clinical trials are suitable for meta-analysis, RCTs on this issue are rarely conducted because of ethical concern or practical difficulty. Nevertheless, all eight pooled studies were of high quality according to the NOS. Abraham et al. have found that meta-analysis of the well-designed non-randomized clinical trial of surgical procedures was probably as accurate as that of RCTs [39]. Second, case volumes of the included studies varied greatly, which may lead to heterogeneity among studies. In such a case, comparisons of surgical results would be influenced by surgeons' experience. Third, DA and LADG BI were performed in different periods, from 2004–2014. Due to the development of laparoscopic instruments, perioperative management protocol and

surgeons' surgical techniques, the clinical outcomes varied and may result in biases. Fourth, long-term functional outcomes in terms of nutritional status and postgastrectomy symptoms weren't directly compared in the present meta-analysis because four pooled studies report using inconsistent assessment scales with different follow-ups. Furthermore, our study was based on studies conducted in East Asia which should extrapolate these data to the Western population prudently, in where the patient population and disease biology may differ [40,41].

Conclusion

Our study suggests that the DA is a safe and feasible procedure as compared with LADG BI. DA broadens the options of gastrointestinal reconstruction following laparoscopic distal gastrectomy and might bring more minimally invasive benefits and better postoperative nutritional status. However, well designed large-scaled studies which balance the baseline of each arm are needed for further confirming the real benefits of DA.

Supporting Information

S1 Text. PRISMA Checklist. (DOC) S2 Text. Search Strategy. (DOC)

Author Contributions

Conceptualization: KWJ GYH.

Data curation: KWJ FT WW.

Formal analysis: KWJ.

Investigation: FT WW.

Methodology: KWJ GYH.

Project administration: KWJ FT WW.

Resources: FT WW.

Software: KWJ.

Supervision: FT WW.

Validation: GYH.

Visualization: KWJ GYH.

Writing - original draft: GYH KWJ.

Writing - review & editing: KWJ FT.

References

- Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014; 32: 627–633. doi: 10.1200/JCO.2013.48.8551 PMID: 24470012
- Hu Y, Ying M, Huang C, Wei H, Jiang Z, Peng X, et al. Oncologic outcomes of laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective cohort study from China. Surg Endosc. 2014; 28: 2048–2056. doi: 10.1007/s00464-014-3426-9 PMID: 24651893

- 3. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14: 101–112. doi: 10.1007/s10120-011-0041-5 PMID: 21573743
- Park YS, Son SY, Oo AM, Jung DH, Shin DJ, Ahn SH, et al. Eleven-year experience with 3000 cases of laparoscopic gastric cancer surgery in a single institution: analysis of postoperative morbidities and long-term oncologic outcomes. Surg Endosc. 2015:
- Sugita H, Kojima K, Inokuchi M, Kato K. Long-term outcomes of laparoscopic gastrectomy for gastric cancer. J Surg Res. 2015; 193: 190–195. doi: 10.1016/j.jss.2014.07.040 PMID: 25193579
- Maruyama K, Katai H. Surgical treatment of gastric cancer in Japan, trend from standardization to individualization. Chirurgia (Bucur). 2014; 109: 722–730.
- Lee SH, Kim IH, Kim IH, Kwak SG, Chae HD. Comparison of short-termoutcomes and acute inflammatory response between laparoscopy-assisted and totally laparoscopic distal gastrectomy for early gastric cancer. Ann Surg Treat Res. 2015; 89: 176–182. doi: 10.4174/astr.2015.89.4.176 PMID: 26446446
- Umemura A, Koeda K, Sasaki A, Fujiwara H, Kimura Y, Iwaya T, et al. Totally laparoscopic total gastrectomy for gastric cancer: literature review and comparison of the procedure of esophagojejunostomy. Asian J Surg. 2015; 38: 102–112. doi: 10.1016/j.asjsur.2014.09.006 PMID: 25458736
- 9. Shinohara T, Kawano S, Tanaka Y, Fujisaki M, Watanabe A, Yamamoto K, et al. Comparison of the cost and outcomes following totally laparoscopic and laparoscopy-assisted distal gastrectomies for gastric cancer: a single-institution comparison. Surg Endosc. 2015:
- Kanaya S, Gomi T, Momoi H, Tamaki N, Isobe H, Katayama T, et al. Delta-shaped anastomosis in totally laparoscopic Billroth I gastrectomy: new technique of intraabdominal gastroduodenostomy. J Am Coll Surg. 2002; 195: 284–287. PMID: 12168979
- Steichen FM. The use of staplers in anatomical side-to-side and functional end-to-end enteroanastomoses. Surgery. 1968; 64: 948–953. PMID: 5687844
- 12. Huang C, Lin M, Chen Q, Lin J, Zheng C, Li P, et al. A modified intracorporeal billroth-I anastomosis after laparoscopic distal gastrectomy for gastric cancer: a safe and feasible technique. Annals of surgical oncology. 2015; 22: 247. doi: 10.1245/s10434-014-3862-8 PMID: 24969440
- 13. Kim DG, Choi YY, An JY, Kwon IG, Cho I, Kim YM, et al. Comparing the short-term outcomes of totally intracorporeal gastroduodenostomy with extracorporeal gastroduodenostomy after laparoscopic distal gastrectomy for gastric cancer: a single surgeon's experience and a rapid systematic review with meta-analysis. Surg Endosc. 2013; 27: 3153–3161. doi: 10.1007/s00464-013-2869-8 PMID: 23494509
- Kitagami H, Morimoto M, Nozawa M, Nakamura K, Tanimura S, Murakawa K, et al. Evaluation of the delta-shaped anastomosis in laparoscopic distal gastrectomy: midterm results of a comparison with Roux-en-Y anastomosis. Surg Endosc. 2014; 28: 2137–2144. doi: 10.1007/s00464-014-3445-6 PMID: 24515263
- Jung MR, Park YK, Seon JW, Kim KY, Cheong O, Ryu SY. Definition and classification of complications of gastrectomy for gastric cancer based on the accordion severity grading system. World J Surg. 2012; 36: 2400–2411. doi: 10.1007/s00268-012-1693-y PMID: 22752074
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003; 327: 557–560. PMID: 12958120
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719–748. PMID: <u>13655060</u>
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188. PMID: 3802833
- Kinoshita T, Shibasaki H, Oshiro T, Ooshiro M, Okazumi S, Katoh R. Comparison of laparoscopy-assisted and total laparoscopic Billroth-I gastrectomy for gastric cancer: a report of short-term outcomes. Surg Endosc. 2011; 25: 1395–1401. doi: 10.1007/s00464-010-1402-6 PMID: 20972584
- Kim MG, Kawada H, Kim BS, Kim TH, Kim KC, Yook JH, et al. A totally laparoscopic distal gastrectomy with gastroduodenostomy (TLDG) for improvement of the early surgical outcomes in high BMI patients. Surg Endosc. 2011; 25: 1076–1082. doi: 10.1007/s00464-010-1319-0 PMID: 20835726
- 21. Wang N, Qiao Q, Wu T, Bao G, Zheng B, Zhou S, et al. [Application study of totally laparoscopic distal gastrectomy with delta-shaped anastomosis]. Zhonghua Wei Chang Wai Ke Za Zhi. 2014; 17: 1111–1114. PMID: 25421771
- Lee HH, Song KY, Lee JS, Park SM, Kim JJ. Delta-shaped anastomosis, a good substitute for conventional Billroth I technique with comparable long-term functional outcome in totally laparoscopic distal gastrectomy. Surg Endosc. 2015; 29: 2545–2552. doi: 10.1007/s00464-014-3966-z PMID: 25427413
- Jeong O, Jung MR, Park YK, Ryu SY. Safety and feasibility during the initial learning process of intracorporeal Billroth I (delta-shaped) anastomosis for laparoscopic distal gastrectomy. Surg Endosc. 2015; 29: 1522–1529. doi: 10.1007/s00464-014-3836-8 PMID: 25294524

- 24. Lin M, Zheng CH, Huang CM, Li P, Xie JW, Wang JB, et al. Totally laparoscopic versus laparoscopyassisted Billroth-I anastomosis for gastric cancer: a case-control and case-matched study. Surg Endosc. 2016:
- Park KB, Kwon OK, Yu W, Jang BC. Body composition changes after totally laparoscopic distal gastrectomy with delta-shaped anastomosis: a comparison with conventional Billroth I anastomosis. Surg Endosc. 2016:
- Goh P, Tekant Y, Isaac J, Kum CK, Ngoi SS. The technique of laparoscopic Billroth II gastrectomy. Surg Laparosc Endosc. 1992; 2: 258–260. PMID: 1341542
- Chen K, Mou YP, Xu XW, Pan Y, Zhou YC, Cai JQ, et al. Comparison of short-term surgical outcomes between totally laparoscopic and laparoscopic-assisted distal gastrectomy for gastric cancer: a 10-y single-center experience with meta-analysis. J Surg Res. 2015; 194: 367–374. doi: 10.1016/j.jss.2014. 10.020 PMID: 25488721
- Gao J, Li P, Li QG, Chen J, Wang DR, Tang D. Comparison between totally laparoscopic and laparoscopically assisted distal gastrectomy for gastric cancer with a short follow-up: a meta-analysis. J Laparoendosc Adv Surg Tech A. 2013; 23: 693–697. doi: 10.1089/lap.2012.0580 PMID: 23678885
- Zhang YX, Wu YJ, Lu GW, Xia MM. Systematic review and meta-analysis of totally laparoscopic versus laparoscopic assisted distal gastrectomy for gastric cancer. World J Surg Oncol. 2015; 13: 116. doi: 10.1186/s12957-015-0532-7 PMID: 25889971
- Kanaya S, Kawamura Y, Kawada H, Iwasaki H, Gomi T, Satoh S, et al. The delta-shaped anastomosis in laparoscopic distal gastrectomy: analysis of the initial 100 consecutive procedures of intracorporeal gastroduodenostomy. Gastric Cancer. 2011; 14: 365–371. doi: <u>10.1007/s10120-011-0054-0</u> PMID: 21573920
- Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014; 21: 891–898. doi: <u>10.1245/</u> s10434-013-3384-9 PMID: 24254205
- Zhou J, Yu P, Shi Y, Tang B, Hao Y, Zhao Y, et al. Evaluation of Clavien-Dindo classification in patients undergoing total gastrectomy for gastric cancer. Med Oncol. 2015; 32: 120. doi: 10.1007/s12032-015-0573-3 PMID: 25788033
- Huang C, Lin M, Chen Q, Lin J, Zheng C, Li P, et al. A modified delta-shaped gastroduodenostomy in totally laparoscopic distal gastrectomy for gastric cancer: a safe and feasible technique. PLoS One. 2014; 9: e102736. doi: 10.1371/journal.pone.0102736 PMID: 25019646
- Huang CM, Lin M, Lin JX, Zheng CH, Li P, Xie JW, et al. Comparision of modified and conventional delta-shaped gastroduodenostomy in totally laparoscopic surgery. World J Gastroenterol. 2014; 20: 10478–10485. doi: 10.3748/wjg.v20.i30.10478 PMID: 25132765
- Postlewait LM, Maithel SK. The importance of surgical margins in gastric cancer. J Surg Oncol. 2016; 113: 277–282. doi: 10.1002/jso.24110 PMID: 26662226
- Takeno S, Noguchi T, Kimura Y, Fujiwara S, Kubo N, Kawahara K. Early and late gastric cancer arising in the remnant stomach after distal gastrectomy. Eur J Surg Oncol. 2006; 32: 1191–1194. PMID: 16797159
- Ahn HS, Kim JW, Yoo MW, Park do J, Lee HJ, Lee KU, et al. Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy. Ann Surg Oncol. 2008; 15: 1632–1639. doi: 10.1245/s10434-008-9871-8 PMID: 18379851
- Sinning C, Schaefer N, Standop J, Hirner A, Wolff M. Gastric stump carcinoma—epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol. 2007; 33: 133–139. PMID: 17071041
- Abraham NS, Byrne CJ, Young JM, Solomon MJ. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol. 2010; 63: 238–245. doi: 10.1016/j.jclinepi.2009.04.005 PMID: 19716267
- 40. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010; 251: 640–646. doi: 10.1097/SLA.0b013e3181d3d29b PMID: 20224369
- Bamboat ZM, Strong VE. Minimally invasive surgery for gastric cancer. J Surg Oncol. 2013; 107: 271– 276. doi: 10.1002/jso.23237 PMID: 22903454